SCHEMBL2809656

SCHEMBL2809656

C[C@@H]1CN(c2nc3c4c(n[nH]c4n2)CCN3Cc2ccccc2)C[C@H](C)O1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3R1 P27986 2/20 0.39
PIK3CA P42336 2/20 0.39
MTOR P42345 5/20 0.36
KCNH2 Q12809 4/20 0.36
BRS3 P32247 3/20 0.35
ALDH1A1 P00352 2/20 0.34
ATM Q13315 2/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
TRPV1 Q8NER1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2809499 0.84 HTR6 (0.46) BRS3ALDH1A1KDM4E
SCHEMBL2812038 0.83 BRS3 (0.44) BRS3TSHRHSD17B10L3MBTL1
SCHEMBL2812360 0.83 DRD4 (0.43) ALDH1A1TSHRMAPK1HSD17B10KDM4E
SCHEMBL2809641 0.82 ALDH1A1 (0.44) ALDH1A1TSHRKDM4EMEN1KMT2A
SCHEMBL2814046 0.81 TSHR (0.47) ALDH1A1TSHRMEN1LMNAKMT2A
SCHEMBL2813985 0.80 KDM4E (0.39) BRS3ALDH1A1TSHRHSD17B10KDM4E
SCHEMBL13131430 0.79 CASP1 (0.44) BRS3ALDH1A1TSHRHSD17B10LMNA
SCHEMBL2814823 0.79 HRH4 (0.40) BRS3ALDH1A1MAPK1HSD17B10KDM4E
SCHEMBL2810794 0.79 GAA (0.45) ALDH1A1TSHRMAPK1KDM4ELMNA
SCHEMBL2810536 0.79 HTR2A (0.48) ALDH1A1TSHRKDM4EMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 PIK3R1 2022/4885PIK3CA 74/4885MTOR 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.